1296 related articles for article (PubMed ID: 33784412)
1. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
[TBL] [Abstract][Full Text] [Related]
2. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
3. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
4. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
[TBL] [Abstract][Full Text] [Related]
5. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
[TBL] [Abstract][Full Text] [Related]
7. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ
Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362
[TBL] [Abstract][Full Text] [Related]
8. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
[TBL] [Abstract][Full Text] [Related]
10. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M
Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
13. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.
Hirani R; Hoad V; Gosbell IB; Irving DO
Transfusion; 2022 Feb; 62(2):292-297. PubMed ID: 34936102
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
[TBL] [Abstract][Full Text] [Related]
15. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
16. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.
Salazar E; Kuchipudi SV; Christensen PA; Eagar T; Yi X; Zhao P; Jin Z; Long SW; Olsen RJ; Chen J; Castillo B; Leveque C; Towers D; Lavinder J; Gollihar J; Cardona J; Ippolito G; Nissly R; Bird I; Greenawalt D; Rossi RM; Gontu A; Srinivasan S; Poojary I; Cattadori IM; Hudson PJ; Josleyn NM; Prugar L; Huie K; Herbert A; Bernard DW; Dye JM; Kapur V; Musser JM
J Clin Invest; 2020 Dec; 130(12):6728-6738. PubMed ID: 32910806
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.
Gordon O; Brosnan MK; Yoon S; Jung D; Littlefield K; Ganesan A; Caputo CA; Li M; Morgenlander WR; Henson SN; Ordonez AA; De Jesus P; Tucker EW; Peart Akindele N; Ma Z; Wilson J; Ruiz-Bedoya CA; Younger MEM; Bloch EM; Shoham S; Sullivan D; Tobian AA; Cooke KR; Larman B; Gobburu JV; Casadevall A; Pekosz A; Lederman HM; Klein SL; Jain SK
JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34855624
[TBL] [Abstract][Full Text] [Related]
18. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
Front Immunol; 2021; 12():739037. PubMed ID: 34594341
[TBL] [Abstract][Full Text] [Related]
19. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
20. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
Viruses; 2021 May; 13(5):. PubMed ID: 34065987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]